GLP 1 allodynia reports link weight loss drugs to burning skin pain

Some people taking Mounjaro, Ozempic and related weight loss drugs report skin that burns at the lightest touch, a symptom doctors call allodynia, the Daily Mail reported on 5 November. GLP 1 allodynia is not listed as a recognized side effect of semaglutide or tirzepatide, the report said, and no study has shown the drugs cause it. The evidence is a handful of case reports, patient accounts and trial counts of a broader symptom. Several patients improved after a dose cut or a pause, so some doctors suspect dose plays a part.

Patients describe skin that feels sunburned

Kaela Knight, a 25 year old nail artist and content creator from Colorado, told the Daily Mail she started tirzepatide in September 2024. She said she weighed 210 pounds at the start and now weighs 125 pounds. In her second month, as her dose went up, she said burning patches appeared on her hips, forearms and the back of her neck. She compared the feeling to sunburn with no visible redness, and said even clothing on her skin could hurt. Each episode lasted 24 to 48 hours, she said, and she puts the total at about ten episodes. She said the symptoms eased once she moved to a lower maintenance dose, and she kept taking the drug throughout.

Knight said her doctor told her other patients had reported the same thing and suggested a vitamin B supplement. The Daily Mail noted there is no established evidence that this treats the problem. Reddit users quoted in the report described burning on the arms, lower back and groin creases that pain relievers and lidocaine gel did not ease. Personal accounts of GLP 1 allodynia like these cannot show cause, and Knight's case adds one more variable. She described her drug as compounded tirzepatide, which is not FDA approved and is not reviewed by the agency for quality before sale. In October one North Carolina pharmacy recalled 22 lots of the drug over sterility doubts.

What case reports on semaglutide side effects show

Published medical reports on GLP 1 allodynia are few and small. An October 2025 report described two patients, according to the Daily Mail. A 56 year old woman treated for obesity developed painful skin within weeks of switching from liraglutide to weekly semaglutide. Her symptoms lasted six weeks and cleared without treatment. A 75 year old man with type 2 diabetes developed burning across his body after moving from oral semaglutide to tirzepatide, which had been raised step by step to the highest approved dose. His pain faded, came back worse, then resolved after he returned to oral semaglutide. The authors suggested the reaction may be dose related, a view the Daily Mail said two cases cannot confirm.

Case reports can flag a possible reaction, but they cannot show that a drug caused it or how often it happens.

A 2025 case series by Stark and colleagues described four patients who developed allodynia after dose increases on weekly semaglutide for obesity. Two stopped the drug and their symptoms cleared. Of the two who kept going, one recovered after four months, and the other paused briefly and restarted with no further pain. Another case series reported allodynia in two patients with severe obesity treated with tirzepatide, and its authors called it the first such series for that drug. These are the clearest written records of tirzepatide skin sensitivity and semaglutide side effects of this kind. Case reports can flag a possible reaction, but they cannot show that a drug caused it or how often it happens.

Retatrutide dysesthesia figures raise a dose question

Trials have not counted allodynia directly. They record dysesthesia, a wider term for burning, tingling or other unpleasant skin feelings, which is not the same as normal touch turning painful. In one trial of high dose oral semaglutide, fewer than 3 percent of 334 people on the drug reported dysesthesia, against none on placebo, the Daily Mail reported. The numbers are higher for retatrutide, an experimental Eli Lilly drug that acts on GLP 1, GIP and glucagon receptors and is not approved. The Daily Mail cited Phase 3 data in which 8.8 percent of patients on one dose and 20.9 percent on a higher dose reported dysesthesia, against 0.7 percent of those on placebo.

The report said these reactions were mostly mild and rarely made people stop treatment. Retatrutide dysesthesia data therefore raise a question, not an answer: are drugs that act on more hormone pathways, or are given at higher doses, more likely to disturb skin sensation? Our earlier report on the retatrutide head to head trial also found more people stopping that drug for side effects. Richard Siegel, an endocrinologist at Tufts Medicine, offered two ideas to the Daily Mail. One is that the drugs act on nerve receptors in the brain and the effect travels through the spinal cord to the skin. The other is that fat loss under the skin may change how nerves sit or fire. Neither idea has been proven.

What doctors advise while the evidence stays thin

Siegel said those affected appear to be mostly people on higher doses, and that it is not clear who else is at risk. He wondered whether people who are more sensitive to pain, such as those with fibromyalgia, might be more prone, but said that is not known. He told the Daily Mail the symptoms "can certainly last days to weeks" and suggested the body may adapt, as it often does with early nausea on these drugs. Doctors may weigh a dose change or a switch, the report said, but patients should not change or stop a prescribed drug on their own. UK GPs made the same point this week about festive dose changes on weight loss jabs.

Burning skin also has other causes, including shingles, migraine and some forms of nerve damage, so a new symptom should not be blamed on the injection by default. Siegel advised patients to note when and where symptoms appear, the time of day, and anything that makes them better or worse. "The more information, the better," he said. Persistent or worsening pain should be checked by a clinician. What is missing on GLP 1 allodynia is basic data, since researchers have not established how often it occurs or who is most at risk. The Daily Mail health report gathers the patient accounts, case reports and trial figures this story draws on, and it names no new study.

Conclusion

GLP 1 allodynia remains a possible but unconfirmed side effect of semaglutide and tirzepatide. The evidence rests on a few case reports, patient accounts and trial counts of dysesthesia, which appear higher with experimental retatrutide at a higher dose. Some patients improved after a dose cut or a pause, but no study has tested that link. Clearer answers need trials that report allodynia separately and wider case collection. Anyone with new skin pain on these drugs should speak to their prescriber before changing a dose.